This program is intended for healthcare professionals only.

Breaking analysis of ASSURE from EASL 2024

Professor Mark Swain discusses the latest updates from the ASSURE trial of seladelpar, presented at EASL 2024, in Milan, Italy. Explore key findings on efficacy, safety, and interim long-term results of this study.

Enjoyed this? You might like: